XBiotech
XBIT
41 hedge funds and large institutions have $5.48M invested in XBiotech in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 8 closing their positions.
1,400% more call options, than puts
Call options by funds: $45K | Put options by funds: $3K
2.1% less ownership
Funds ownership: 9.63% → 7.53% (-2.1%)
15% less funds holding
Funds holding: 48 → 41 (-7)
30% less capital invested
Capital invested by funds: $7.81M → $5.48M (-$2.32M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$461K |
| 2 |
Morgan Stanley
New York
|
+$103K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$74K |
| 4 |
Jane Street
New York
|
+$34.4K |
| 5 |
PAP
Persistent Asset Partners
Hong Kong
|
+$33.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.28M |
| 2 |
Millennium Management
New York
|
-$693K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$106K |
| 4 |
HF
HRT Financial
New York
|
-$69K |
| 5 |
BlackRock
New York
|
-$33.9K |
XBIT Hedge Fund Activity: Q4 2025 in Review
41 of the 8,277 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q4 2025, worth a combined $5.48M — down 30% from $7.81M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of XBIT and 4 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 8 added.
The largest buyer was Ameriprise, opening a new position worth an estimated $461K. The largest seller was Vanguard Group, cutting an estimated $1.28M.
- 41 institutional investors held XBiotech (XBIT) as of Q4 2025, down from 48 in Q3 2025.
- Funds reported $5.48M of XBiotech stock for Q4 2025, down 30% quarter-over-quarter.
- 4 funds opened new XBiotech positions in Q4 2025 and 8 closed out, a net change of -4 holders.
- The largest XBiotech buyer in Q4 2025 was Ameriprise, an estimated $461K added.
- The largest XBiotech seller in Q4 2025 was Vanguard Group, an estimated $1.28M sold.
Based on aggregated 13F filings for Q4 2025.